801 related articles for article (PubMed ID: 31712207)
21. Activity of Simulated Human Dosage Regimens of Meropenem and Vaborbactam against Carbapenem-Resistant Enterobacteriaceae in an
Sabet M; Tarazi Z; Rubio-Aparicio D; Nolan TG; Parkinson J; Lomovskaya O; Dudley MN; Griffith DC
Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29133570
[TBL] [Abstract][Full Text] [Related]
22. Pharmacodynamic evaluation of meropenem, cefepime, or aztreonam combined with a novel β-lactamase inhibitor, nacubactam, against carbapenem-resistant and/or carbapenemase-producing Klebsiella pneumoniae and Escherichia coli using a murine thigh-infection model.
Hagihara M; Kato H; Sugano T; Okade H; Sato N; Shibata Y; Sakanashi D; Asai N; Koizumi Y; Suematsu H; Yamagishi Y; Mikamo H
Int J Antimicrob Agents; 2021 May; 57(5):106330. PubMed ID: 33789129
[TBL] [Abstract][Full Text] [Related]
23. Epidemiology of Carbapenem Resistance Determinants Identified in Meropenem-Nonsusceptible
Kazmierczak KM; Karlowsky JA; de Jonge BLM; Stone GG; Sahm DF
Antimicrob Agents Chemother; 2021 Jun; 65(7):e0200020. PubMed ID: 33972241
[TBL] [Abstract][Full Text] [Related]
24. Diversity of resistance mechanisms in carbapenem-resistant Enterobacteriaceae at a health care system in Northern California, from 2013 to 2016.
Senchyna F; Gaur RL; Sandlund J; Truong C; Tremintin G; Kültz D; Gomez CA; Tamburini FB; Andermann T; Bhatt A; Tickler I; Watz N; Budvytiene I; Shi G; Tenover FC; Banaei N
Diagn Microbiol Infect Dis; 2019 Mar; 93(3):250-257. PubMed ID: 30482638
[TBL] [Abstract][Full Text] [Related]
25.
Hackel MA; Lomovskaya O; Dudley MN; Karlowsky JA; Sahm DF
Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29084745
[TBL] [Abstract][Full Text] [Related]
26. Comparative Activities of Novel Therapeutic Agents against Molecularly Characterized Clinical Carbapenem-Resistant
Teo JQ; Chang HY; Tan SH; Tang CY; Ong RT; Ko KKK; Chung SJ; Tan TT; Kwa AL
Microbiol Spectr; 2023 Jun; 11(3):e0100223. PubMed ID: 37184408
[TBL] [Abstract][Full Text] [Related]
27. In vitro activity of meropenem combined with vaborbactam against KPC-producing Enterobacteriaceae in China.
Zhou M; Yang Q; Lomovskaya O; Sun D; Kudinha T; Xu Z; Zhang G; Chen X; Xu Y
J Antimicrob Chemother; 2018 Oct; 73(10):2789-2796. PubMed ID: 29982437
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetics/Pharmacodynamics of Vaborbactam, a Novel Beta-Lactamase Inhibitor, in Combination with Meropenem.
Griffith DC; Sabet M; Tarazi Z; Lomovskaya O; Dudley MN
Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30397063
[TBL] [Abstract][Full Text] [Related]
29. Ceftazidime-avibactam activity against a challenge set of carbapenem-resistant Enterobacterales: Ompk36 L3 alterations and β-lactamases with ceftazidime hydrolytic activity lead to elevated MIC values.
Castanheira M; Doyle TB; Hubler C; Sader HS; Mendes RE
Int J Antimicrob Agents; 2020 Jul; 56(1):106011. PubMed ID: 32417206
[TBL] [Abstract][Full Text] [Related]
30. Activity of Meropenem-Vaborbactam against Bacterial Isolates Causing Pneumonia in Patients in U.S. Hospitals during 2014 to 2018.
Carvalhaes CG; Shortridge D; Sader HS; Castanheira M
Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31907187
[TBL] [Abstract][Full Text] [Related]
31. Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations.
Zhanel GG; Lawrence CK; Adam H; Schweizer F; Zelenitsky S; Zhanel M; Lagacé-Wiens PRS; Walkty A; Denisuik A; Golden A; Gin AS; Hoban DJ; Lynch JP; Karlowsky JA
Drugs; 2018 Jan; 78(1):65-98. PubMed ID: 29230684
[TBL] [Abstract][Full Text] [Related]
32. Meropenem and Vaborbactam: Stepping up the Battle against Carbapenem-resistant Enterobacteriaceae.
Jorgensen SCJ; Rybak MJ
Pharmacotherapy; 2018 Apr; 38(4):444-461. PubMed ID: 29427523
[TBL] [Abstract][Full Text] [Related]
33. In vitro activity of plazomicin against β-lactamase-producing carbapenem-resistant Enterobacteriaceae (CRE).
Zhang Y; Kashikar A; Bush K
J Antimicrob Chemother; 2017 Oct; 72(10):2792-2795. PubMed ID: 29091224
[TBL] [Abstract][Full Text] [Related]
34.
Castanheira M; Davis AP; Mendes RE; Serio AW; Krause KM; Flamm RK
Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29866862
[TBL] [Abstract][Full Text] [Related]
35. Imipenem/relebactam activity compared to other antimicrobials against non-MBL-producing carbapenem-resistant Enterobacteriaceae from an academic medical center.
Kulengowski B; Burgess DS
Pathog Dis; 2019 Jun; 77(4):. PubMed ID: 31365075
[TBL] [Abstract][Full Text] [Related]
36. Phenotypic and molecular characteristics of carbapenem-resistant Enterobacteriaceae in a health care system in Los Angeles, California, from 2011 to 2013.
Pollett S; Miller S; Hindler J; Uslan D; Carvalho M; Humphries RM
J Clin Microbiol; 2014 Nov; 52(11):4003-9. PubMed ID: 25210072
[TBL] [Abstract][Full Text] [Related]
37. Activity of Meropenem-Vaborbactam in Mouse Models of Infection Due to KPC-Producing Carbapenem-Resistant Enterobacteriaceae.
Sabet M; Tarazi Z; Nolan T; Parkinson J; Rubio-Aparicio D; Lomovskaya O; Dudley MN; Griffith DC
Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29109160
[TBL] [Abstract][Full Text] [Related]
38. Activity of meropenem/vaborbactam against international carbapenem-resistant Escherichia coli isolates in relation to clonal background, resistance genes, resistance to comparators and region.
Johnston BD; Thuras P; Porter SB; Castanheira M; Johnson JR
J Glob Antimicrob Resist; 2021 Mar; 24():190-197. PubMed ID: 33460842
[TBL] [Abstract][Full Text] [Related]
39. Meropenem-vaborbactam for adults with complicated urinary tract and other invasive infections.
Albin OR; Patel TS; Kaye KS
Expert Rev Anti Infect Ther; 2018 Dec; 16(12):865-876. PubMed ID: 30372359
[TBL] [Abstract][Full Text] [Related]
40. Effect of Colistin, Fosfomycin and Meropenem/Vaborbactam on Carbapenem-Resistant
Shrief R; El-Ashry AH; Mahmoud R; El-Mahdy R
Infect Drug Resist; 2022; 15():6203-6214. PubMed ID: 36324668
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
